# Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells

**Authors:** Angelica M. Merlot, Sumit Sahni, Darius J.R. Lane, Ashleigh M. Fordham, Namfon Pantarat, David E. Hibbs, Vera Richardson, Munikumar R. Doddareddy, Jennifer A. Ong, Michael L.H. Huang, Des R. Richardson, Danuta S. Kalinowski

PMC · DOI: 10.18632/oncotarget.3606 · 2015-03-15

## TL;DR

This study shows how human serum albumin enhances the cancer cell targeting and effectiveness of a drug called Dp44mT through two specific uptake mechanisms.

## Contribution

The discovery of two saturable mechanisms for Dp44mT uptake, with one being HSA-dependent, is a novel finding.

## Key findings

- HSA significantly increases Dp44mT uptake by cancer cells through a second saturable mechanism.
- The HSA-mediated uptake mechanism has lower affinity but higher capacity compared to the first mechanism.
- Enhanced Dp44mT targeting by HSA increases apoptosis in cancer cells.

## Abstract

Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) demonstrates potent anti-cancer activity. We previously demonstrated that 14C-Dp44mT enters and targets cells through a carrier/receptor-mediated uptake process. Despite structural similarity, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and pyridoxal isonicotinoyl hydrazone (PIH) enter cells via passive diffusion. Considering albumin alters the uptake of many drugs, we examined the effect of human serum albumin (HSA) on the cellular uptake of Dp44mT, Bp4eT and PIH. Chelator-HSA binding studies demonstrated the following order of relative affinity: Bp4eT≈PIH>Dp44mT. Interestingly, HSA decreased Bp4eT and PIH uptake, potentially due to its high affinity for the ligands. In contrast, HSA markedly stimulated Dp44mT uptake by cells, with two saturable uptake mechanisms identified. The first mechanism saturated at 5-10 μM (Bmax:1.20±0.04 × 107 molecules/cell; Kd:33±3 μM) and was consistent with a previously identified Dp44mT receptor/carrier. The second mechanism was of lower affinity, but higher capacity (Bmax:2.90±0.12 × 107 molecules/cell; Kd:65±6 μM), becoming saturated at 100 μM and was only evident in the presence of HSA. This second saturable Dp44mT uptake process was inhibited by excess HSA and had characteristics suggesting it was mediated by a specific binding site. Significantly, the HSA-mediated increase in the targeting of Dp44mT to cancer cells potentiated apoptosis and could be important for enhancing efficacy.

## Linked entities

- **Proteins:** ALB (albumin)
- **Chemicals:** Dp44mT (PubChem CID 10334137), HSA (PubChem CID 845)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, TF (transferrin) [NCBI Gene 7018] {aka HEL-S-71p, PRO1557, PRO2086, TFQTL1}, HNRNPC (heterogeneous nuclear ribonucleoprotein C) [NCBI Gene 3183] {aka HNRNP, HNRPC, MRD74, SNRPC}, SPARC (secreted protein acidic and cysteine rich) [NCBI Gene 6678] {aka BM-40, OI17, ON, ONT}, CUBN (cubilin) [NCBI Gene 8029] {aka IFCR, IGS, IGS1, MGA1, gp280}, CAT (catalase) [NCBI Gene 847], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, FCGRT (Fc gamma receptor and transporter) [NCBI Gene 2217] {aka FCRN, FcgammaRn, alpha-chain}
- **Diseases:** pancreatic adenocarcinoma (MESH:D010190), metastasis (MESH:D009362), neuroepithelioma (MESH:D018241), mitochondrial (MESH:D028361), Tumor (MESH:D009369), non-small cell lung cancer (MESH:D002289), breast cancer (MESH:D001943), DMS-53 lung carcinoma (MESH:D008175), cytotoxicity (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Hysterothylacium sp. SA (species) [taxon 1884613]
- **Cell lines:** P8811 — Atilax paludinosus (Marsh mongoose), Finite cell line (CVCL_6365), MRC-5 — Homo sapiens (Human), Finite cell line (CVCL_0440), DMS-53 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_1177), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), MCF-7 breast cancer — Homo sapiens (Human), Transformed cell line (CVCL_WC49), SK-N-MC — Homo sapiens (Human), Askin tumor, Cancer cell line (CVCL_0530), HepG2 hepatocellular carcinoma — Homo sapiens (Human), Hepatocellular carcinoma, Cancer cell line (CVCL_A1AS), HepG2 hepatoma — Mus musculus (Mouse), Hepatocellular carcinoma of the mouse, Cancer cell line (CVCL_H613), SK-Mel-28 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0526), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4496362/full.md

---
Source: https://tomesphere.com/paper/PMC4496362